Helen brings more than 20 years of investor and operator experience in healthcare and life sciences as an Operating Partner at BOLD. Previously, Helen spent more than thirteen years developing therapeutics in Inflammation and Oncology within Amgen’s R&D organization and later led translational sciences at an oncology start-up, TORL Biotherapeutics. As an investor, Helen led healthcare investing for several years for the Fund@Caltech, a seed stage fund supporting multiple successful spinouts from the Institute. Helen received her BS degree in Microbiology from Texas A&M University, her PhD in Oncological Sciences from the University of Utah, and her postdoctoral training at Caltech studying developmental neurobiology and biophysics.